Antioxidant-PPARalpha interaction and hypertension
Antioxidant-PPARalpha interaction and hypertension
批准号:
8968860
负责人:
Terry D Hinds
金额:
$15.42万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-11-15 至 2019-10-31
关键词:
AdipocytesAdipose tissueAdultAffectAgonistAnimal ModelAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsAnusAtherosclerosisAttenuatedBilirubinBiliverdin reductaseBiliverdineBindingBlood VesselsBurn injuryCardiovascular DiseasesCardiovascular systemCentral obesityClinicalClinical ManagementDataDevelopmentDiabetes MellitusDiastolic blood pressureDietEpidemicEventFatty acid glycerol estersFunctional disorderGilbert DiseaseGlucoseHealth ExpendituresHemeHomeostasisHormonalHormonesHyperbilirubinemiaHypertensionIndividualInflammatoryInsulinInsulin ResistanceInterleukin-1Interleukin-6KnowledgeLeadLigandsLinkLipidsMediatingMedicalMetabolic syndromeMolecularNonesterified Fatty AcidsNuclear ReceptorsObese MiceObesityOutcomeOverweightOxidative StressOxygenasesPPAR alphaPlasmaPopulationProductionPropertyProteinsPublic HealthReactive Oxygen SpeciesRegulator GenesResearchResistanceRisk FactorsSerumSignal TransductionSystemTNF geneTestingTissue ExpansionVascular DiseasesVisceraladipokinesadiponectinbasecostcytokinediabeticfatty acid metabolismglucose uptakehumanized mousein vitro Modelin vivolipid biosynthesismouse modelnovelpreventresponsesubcutaneousvascular endothelial dysfunctionvascular inflammation
中文摘要
描述(由申请人提供):肥胖是一个主要的公共卫生问题,已导致全球流行,是糖尿病、动脉粥样硬化和心血管疾病的潜在原因。内脏和皮下脂肪过多预示着血管疾病和相关并发症,包括血管功能障碍、胰岛素抵抗和脂肪燃烧核受体、过氧化物酶体增殖物激活受体α (PPARα)水平降低。PPARα除了调节脂肪酸代谢外,在血管炎症和动脉粥样硬化中具有抗炎特性,很可能是通过诱导脂联素。脂联素是一种脂肪特异性激素,具有抗炎和血管保护作用,其循环水平在肥胖中降低。肥胖通过增加活性氧增加氧化应激,同时降低血红素加氧酶(HO)、胆红素和PPARα等关键细胞保护系统的表达和活性,同时增加炎症细胞因子和胰岛素抵抗。肥胖介导的脂肪细胞功能障碍的这些后果(PPARα/脂联素降低和炎性脂肪因子如TNFα、IL-1和IL-6增加)可能导致血管功能障碍,这是血管疾病和高血压的前奏。在这里,我们提供了新的数据,胆红素激活PPARα活性,这可能是一种内源性配体激动剂。我们假设这三种保护因子,胆红素,PPARα和脂联素,是不可分割地联系在一起形成一个功能模块,脂肪细胞中任何这些因子的缺乏都会导致与肥胖相关的脂肪细胞和血管功能障碍。我们将在体外和体内测试该模型,以证明胆红素具有抗肥胖和抗糖尿病的保护特性,这是由PPARα介导的,可以减少血管功能障碍。
英文摘要
DESCRIPTION (provided by applicant): Obesity is a major public health concern that has led to a worldwide epidemic and is the underlying cause of diabetes, atherosclerosis and cardiovascular disease. Excessive visceral and subcutaneous fat is predictive of vascular disease and associated complications, including vascular dysfunction, insulin resistance and decreased levels of the fat burning nuclear receptor, peroxisome proliferator-activated receptor α (PPARα). In addition to PPARα regulating fatty acid metabolism, it has anti-inflammatory properties in vascular inflammation and atherosclerosis, most likely through induction of adiponectin. Adiponectin is an adipose- specific hormone with anti-inflammatory and vascular protective properties, and its circulating levels are decreased in obesity. Obesity increases oxidative stress by enhancing reactive oxygen species and simultaneously decreases expression and activity of key cytoprotective systems including heme oxygenase (HO) and bilirubin as well as PPARα, while increasing inflammatory cytokines and insulin resistance. These consequences of obesity-mediated adipocyte dysfunction (decreased PPARα/adiponectin and increased inflammatory adipokines such as TNFα, IL-1 and IL-6) may lead to vascular dysfunction, which is a prelude to vascular disease and hypertension. Here we provide novel data that bilirubin activates PPARα activity, which may function as an endogenous ligand agonist. We hypothesize that the three protective factors, bilirubin, PPARα and adiponectin, are inextricably linked forming a functional module and a deficiency in any of these factors within adipocytes leads to adipocyte and vascular dysfunction that is associated with obesity. We will test this model in vitro and in vivo to show that bilirubin has protective ani-obese and anti- diabetic properties that are mediated by PPARα that reduces vascular dysfunction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Liver Signaling Pathways Controlling Adiposity
-
批准号:10596569
-
项目类别:
-
资助金额:$41.37万
-
财政年份:2020
-
负责人:Terry D Hinds
-
依托单位:
Novel Liver Signaling Pathways Controlling Adiposity
-
批准号:10210389
-
项目类别:
-
资助金额:$40.84万
-
财政年份:2020
-
负责人:Terry D Hinds
-
依托单位:
Novel Liver Signaling Pathways Controlling Adiposity
-
批准号:10376254
-
项目类别:
-
资助金额:$41.01万
-
财政年份:2020
-
负责人:Terry D Hinds
-
依托单位:
Novel Liver Signaling Pathways Controlling Adiposity
-
批准号:10763473
-
项目类别:
-
资助金额:$6.9万
-
财政年份:2020
-
负责人:Terry D Hinds
-
依托单位:
Novel Liver Signaling Pathways Controlling Adiposity
-
批准号:10320589
-
项目类别:
-
资助金额:$42.05万
-
财政年份:2020
-
负责人:Terry D Hinds
-
依托单位:
Fatty acid Control Obesity and the Metabolic Syndrome via TPR proteins
-
批准号:7807886
-
项目类别:
-
资助金额:$3.44万
-
财政年份:2009
-
负责人:Terry D Hinds
-
依托单位:
Fatty acid Control Obesity and the Metabolic Syndrome via TPR proteins
-
批准号:7676943
-
项目类别:
-
资助金额:$3.4万
-
财政年份:2009
-
负责人:Terry D Hinds
-
依托单位:
海外基金